MarketWatch In-vitro data on Basilea's investigational anti-Gram-negative antibiotic BAL30072, currently in phase 1 clinical development, were also presented, demonstrating synergy between BAL30072 and antibiotics from the carbapenem class against recent clinical ... 更多 »
TIME In some countries, more than half of people infected with K. pneumonia bacteria won't respond to carbapenems . A similar percentage of patients with E. coli infections won't be helped by taking fluoroquinolone antibiotics. The growth of drug-resistant ... 更多 »
